India will set up the fund to encourage companies to manufacture pharmaceutical ingredients domestically.

The turmoil couldn’t have hit at a worse time for the $110 billion conglomerate.

The US FDA said it had found similar quality control lapses at Lupin’s two other sites too.

India’s No. 2 retailer by turnover, Future is seeking a valuation of about $281 mn from Amazon for 10% stake.

The aim is to reduce the Apollo shares pledged by the family as collateral to lenders.

Shanghvi believes market watchers are underestimating the potential in China for India’s largest drugmaker.

In India, its hunt for alternatives has led it to tap into a rich vein of “ethnic drinks”.

Ambani wants to marry the might of 9,900-plus retail stores and 280-million telecom user base.

Kapoor’s removal shows how far the RBI is preparing to go to root out a system-wide legacy of shoddy lending.

The drugmaker’s current market capitalization stands at around $940 million.

The Draft Pharmaceutical Policy has made no progress since opposition emerged from the industry and among some government agencies.

Sun was tipped into a loss this quarter after it agreed to pay plaintiffs including Canadian rival Apotex to settle a lawsuit over sleep-di...

The founder of Sun Pharma has seen his net worth fall to $11.1 billion on Bloomberg Index.

Banks where capital adequacy ratio falls below the RBI’s threshold may see the firm being merged, or wound up, according to the document.

As of September, the company had about $152 million in cash, and in its most recent earnings conference call said it had about $810 million...

The Indian pharmaceutical industry’s explosive growth over the past decade has made the nation host to the most FDA-approved plants outside...

Deutsche Bank’s G10 FX Carry Basket index fell 3.3% last month, the biggest decline since May 2012, reducing its gain this year to 1.6%.